Search
News
24H | Chinese ADRs & ETFs Fall. Kingsoft Cloud, CHAU Down 6%; XPeng, GDS Down Around 4%; Baidu, Alibaba Down 3%; Hesai Group, WeRide Down over 2%
Chinese ADRs & ETFs fell in overnight trading. Kingsoft Cloud, CHAU fell 6%; XPeng, GDS down around 4%; Baidu, Alibaba down 3%; Hesai Group, WeRide down over 2%.Tiger News
Fri, Jun 26
Crypto Daily｜Michael Saylor’S Misfiring Funding Model Jolts Bitcoin Traders; Invesco Files Tokenized Fund for Stablecoin Reserves
Crypto Daily is our column tracking crypto market trends, offering timely insights and valuable updates to keep you informed.Crypto NewsMichael Saylor’s Misfiring Funding Model Jolts Bitcoin TradersFears that Michael Saylor’s Bitcoin buying machine is beginning to seize up are spilling across the cr...Tiger News
Fri, Jun 26
24H | Chip, Storage Shares Extend Declines. ON Semiconductor Down 9%; SOXL Down 8%; SanDisk Down Nearly 6%; Micron Down 5%; ARM, Marvell, Western Digital, Intel Down over 4%
Chip, storage shares extended declines in overnight trading. ON Semiconductor down 9%; SOXL down 8%; SanDisk down nearly 6%; Micron, Wolfspeed down around 5%; ARM, Marvell, Western Digital, Intel down over 4%.Tiger News
Fri, Jun 26
HK Movers | Storage, Optical Stocks Plunge. 2x Leveraged ETF Related to Samsung Falls 11%; YOFC, 2x Leveraged SK Hynix ETF Down 10%; Time Intercon, Montage Tech Down 7%
Storage, optical stocks plunged in Hong Kong market. 2x Leveraged ETF related to Samsung fell 11%; YOFC, 2x Leveraged SK Hynix ETF down 10%; Time Intercon, Montage Tech down 7%.Tiger News
Fri, Jun 26
Top Calls on Wall Street: Micron, Apple, Tesla, Intel, Qualcomm, Netflix, SanDisk, CoreWeave & More
Here are Thursday’s biggest calls on Wall Street:Bank of America reiterates Micron as buyThe firm says it sees “stronger for longer pricing” following Micron’s earnings report on Wednesday.“MU delivered another strong quarter, reinforcing our constructive view on memory’s rolein AI and the increasin...Tiger News
Thu, Jun 25
Dow Jumps Over 1% With Caterpillar up 5%, Honeywell up 4%
Dow Jones Industrial Average jumped more than 1% in morning trading. Caterpillar rose 5%; Honeywell rose 4%; Sherwin-Williams, Merck, and Johnson & Johnson rose 3%; UnitedHealth, JPMorgan Chase, American Express, Amgen, 3M, and Visa rose 2%.Tiger News
Thu, Jun 25
Hong Kong's First Listed Peptide Innovative Drug Company: Micot Pharma Innovative Pipeline Poised for Breakthrough, Clear Positioning in the Cardio-Renal-Metabolic Space
On 24 June, Micot Pharma-B (02335.HK) officially listed on the Hong Kong Stock Exchange, becoming the first innovative drug company under Chapter 18A of the Hong Kong Listing Rules with a peptide core technology platform — the long-awaited “Hong Kong’s First Peptide Innovative Drug Stock.”On its first trading day, its stock price performed strongly, closing at HK$36.90, more than double the offering price of HK$18.20, with its market capitalization quickly surpassing HK$10 billion. Prior to listing, the Hong Kong public offering was oversubscribed by more than 1,000 times, and the international placement was also oversubscribed, reflecting a recovery in market appetite for differentiated innovative drugs.As Hong Kong's first listed peptide-innovative drug company, Micot Pharma has spent over a decade focusing on dual- and multi-functional peptide innovative drugs, building a peptide drug portfolio spanning kidney, metabolic, cardiovascular, and cerebrovascular diseases. The company has self-developed a comprehensive pipeline consisting of one core product and six key candidates, all seven of which have entered clinical stages, with six filing simultaneously in both the PRC and the U.S., making it the Chinese company with the most innovative peptide drugs in clinical stages.MT1013: A Differentiated Pipeline Recognized by International Academic Institutions, with a Clear Commercialization PathMicot Pharma's core product, MT1013, is a dual-target receptor agonist polypeptide that simultaneously targets the CaSR and the OGP receptor. It primarily targets chronic kidney disease-secondary hyperparathyroidism (CKD-SHPT), a common complication of chronic kidney disease. The global patient population is projected to reach 188 million by 2030, with the related drug market in Chinese Mainland valued at approximately RMB 5 billion. This condition is not merely an elevation of parathyroid hormone (iPTH), but a systemic issue involving calcium-phosphorus imbalance, abnormal bone metabolism, and increased cardiovascular risk.Current mainstream drugs, such as cinacalcet and etelcalcetide, primarily lower iPTH but still have limitations in areas including blood calcium reduction, gastrointestinal side effects, improvements in bone metabolism, and overall target achievement rates. MT1013's differentiation lies in its dual-target synergy: it lowers iPTH through CaSR receptor while promoting bone metabolism improvement through OGP-related mechanisms. It aims to simultaneously improve multiple indicators, including iPTH, blood calcium, blood phosphorus, and bone metabolism.According to Phase II head-to-head clinical data disclosed by the company, MT1013 demonstrated a 2.2- to 2.5-fold higher comprehensive target achievement rate for iPTH, serum calcium, and serum phosphorus compared with etelcalcetide, while also significantly reducing FGF23 levels, a biomarker directly linked to cardiovascular risk. At the same time, MT1013's clinical value has also received substantial recognition from leading international academic institutions. Its research data was accepted as a "Late-Breaking" at the American Society of Nephrology (ASN) Annual Meeting, the highest-level recognition for innovative therapies on the world's most influential academic stage in nephrology.Currently, MT1013's Phase III clinical trial has completed patient enrolment. The company expects to submit an NDA application in early 2027 and achieve commercialization in early 2028. In 2026, the company entered into an exclusive commercialization partnership agreement with Everest Medicines (stock code: 1952.HK), covering China and the Asia-Pacific region (excluding Japan). The total upfront and milestone payments could reach up to RMB 1.24 billion, with RMB 200 million already received.XTL6001: Not Just Another GLP-1, but an Extension into Cardio-Renal-Metabolic TerritoryIf MT1013 serves as the near-term commercialization milestone, XTL6001 would represent Micot Pharma's second growth driver. XTL6001 is the world's first and only GLP-1R/GCGR/MasR tri-target agonist to have received IND approvals in both the PRC and the U.S. Compared with traditional GLP-1 or GLP-1/GIP dual-target drugs, its differentiation goes beyond "three targets". By introducing MasR, it brings significant hepatic and renal protective advantages. Activation of this pathway exerts anti-inflammatory, anti-fibrotic, and vasodilatory effects that directly address key mechanisms in CKD progression. This naturally extends its indication from weight loss to CKD with proteinuria and other diseases, addressing the shortcomings of single-target GLP-1 drugs in renal benefits. Additionally, XTL6001 offers multiple metabolic regulatory functions such as fat reduction and muscle preservation, providing patients with an integrated treatment approach from body composition optimization to target organ protection.Its indications extend from weight loss to CKD with proteinuria, MASH, and other conditions, targeting the renal disease gaps that GLP-1 drugs cannot cover. Preclinical studies show that XTL6001 achieves a greater reversal of fatty liver than tirzepatide and can further reduce the urine albumin-to-creatinine ratio (UACR) by an additional 15%–20% compared with finerenone. According to the company disclosure, the Phase I clinical trial of XTL6001 has been completed.MT1002 and MT200605: First and Only in the WorldIn addition to MT1013 and XTL6001, Micot Pharma has also built two high-potential product candidates, MT1002 and MT200605, targeting stroke and coronary heart disease. These are among the most burdensome cardiovascular and cerebrovascular conditions globally, yet remain areas with a severe shortage of innovative treatments. MT1002 is a coagulation factor II and GP IIb/IIIa dual-target peptide antagonist, primarily designed for clinical needs in anticoagulation and anti-thrombosis. Using a single molecule, it could address the existing challenge of balancing bleeding and ischemia in multi-drug combination regimens. MT200605 targets acute ischemic stroke (AIS) through dual mechanisms of promoting nerve regeneration and scavenging oxygen-free radicals, thereby blocking the cascade of pathological damage after AIS via two pathways. MT1002 is currently in Phase II clinical trials in both the U.S. and the PRC, demonstrating good efficacy and safety across different patient populations and dose levels. Meanwhile, MT200605 has completed patient enrolment for Phase II clinical trials in the PRC, with Phase I clinical studies demonstrating favorable safety and tolerability profile.Dual Endorsement from State-Owned and Industrial Capital: A Clearer Commercialization PathMicot Pharma brought in Qiyuan Hong Kong, Everest Medicines, and Summit Capital as cornerstone investors for this IPO, creating a structure involving local government funds, industrial capital, and professional healthcare investment institutions. Among them, Qiyuan Hong Kong represents support from Shaanxi provincial state-owned capital; Summit Capital represents recognition from professional healthcare investment; and Everest Medicines carries the most direct industrial significance. Everest Medicines had already signed an exclusive commercialization agreement with the company for MT1013. Its participation as a cornerstone investor in this IPO signifies the relationship has been upgraded from a purely commercial partnership to a dual endorsement of "industrial collaboration + equity subscription."From the PRC to the World: An Integrated Platform for First-in-Class Peptide DrugsMicot Pharma's underlying capability lies in establishing an integrated drug R&D system that supports global First-in-Class drugs from molecular design to clinical translation, further extending into an end-to-end global industrial chain platform spanning discovery, development, and commercialization. This positions the company not merely as a single-pipeline Chapter 18A company, but as a peptide innovative drug enterprise with platform-based innovation, global regulatory registration, international clinical execution, and industrialization capabilities. The early success of MT1013 and XTL6001 underscores Micot Pharma's ability to "select the right targets and understand the disease" and demonstrates the coordinated execution capacity of its end-to-end platform.The IPO raised approximately HK$1.067 billion, with proceeds primarily allocated to core pipeline clinical development and registration, commercialization rollout, development of product candidates, and R&D of the peptide technology platform. With a huge potential market, strong backing from government and strategic shareholders, and ample IPO funding, Micot Pharma has established a solid foundation to progressively realize its clinical and commercial value over the coming years, while acting as a key driving force for Chinese peptide innovation to expand globally.-End-25/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Thu, Jun 25
Dongfeng unveils global expansion strategy at Hong Kong auto expo
On June 18, 2026, the 2026 International Automotive and Supply Chain Expo (Hong Kong), also known as Auto HK, opened at AsiaWorld-Expo.During the expo, Dongfeng Motor Corporation, a Chinese automaker, held a brand strategy launch event, officially unveiling its " Skyward Sailing Plan " global expansion ambition aimed at strengthening its presence in Hong Kong and other right-hand-drive markets worldwide.Among those attending the event were Dr. Wingco Lo, a member of the National Committee of the Chinese People's Political Consultative Conference, chief chairman of the Auto HK organizing committee and president of the Chinese Manufacturers' Association of Hong Kong; Yu Xiao, chairman of the Auto HK organizing committee and vice chairman and president of the Hong Kong Chinese Enterprises Association; Tam Yiu-chung, secretary-general of the Hong Kong Coalition and vice chairman of the Chinese Association of Hong Kong and Macao Studies; and Liu Yan, deputy secretary-general of the China Association of Automobile Manufacturers.Dongfeng unveils "Setting Sail" global expansion strategyYou Zheng, Deputy President of Dongfeng Motor Corporation, said technological innovation would remain the company's key driver for international expansion. As Hong Kong has been serving as a strategic hub for Dongfeng's development in right-hand-drive markets, it supports the brand expansion into Southeast Asia, Australia and New Zealand, the Middle East and other regions.Under its "Skyward Sailing Plan”, Dongfeng said it would focus on three technology pillars: "Tianyuan Intelligence Plan" for smart mobility, "Pure Sky Zero-Carbon Plan" for low-carbon technologies, and "All-Domain Safety" to enhance vehicle safety.Under the blueprint, Dongfeng said it would invest more than 100 billion yuan ($14.8 billion) over the next five years to implement a three-stage international expansion plan covering exporting vehicles, establishing local production, and developing overseas industrial ecosystems. The company plans to launch 55 overseas-specific vehicle models, establish 6,000 service outlets, build 10 large-scale overseas production bases with localized manufacturing accounting for 50% of output, and establish five overseas research and development centers and two overseas financial platforms. Dongfeng also aims to increase the proportion of locally hired overseas employees to 70%. By 2030, the company aims to achieve global sales of 5 million vehicles, with the share of new energy vehicles exceeding 70% and the proportion of overseas sales reaching 40%.Four-brand lineup targets right-hand-drive marketsAt the exhibition, Dongfeng showcased vehicles from four brands covering mass-market, smart family, premium intelligent and off-road segments. The company said its existing right-hand-drive models under the mass-market brand will remain the core of its market strategy, while development of vehicles under the three other premium brands is being accelerated. Together with its Hong Kong flagship store and supporting service network, Dongfeng said it aims to strengthen its presence in right-hand-drive markets through an integrated product and after-sales strategy.Several dedicated right-hand-drive models under the mass-market brand, including the DONGFENG 007, DONGFENG VIGO and DONGFENG BOX, have already been launched in Hong Kong. The company said sales in Hong Kong during the first quarter of 2026 provided support for its expansion in mass-market right-hand-drive segments.Development of right-hand-drive models under the Epicland, Voyah and MHero brands is also progressing, with plans to respectively expand into smart family vehicles, premium luxury vehicles and professional off-road segments.Dongfeng also said its Hong Kong flagship store has come online, offering maintenance services for right-hand-drive vehicles, localized charging solutions and tailored financing services, while supporting the expansion of its dealer network in Southeast Asia to provide integrated sales and after-sales services for right-hand-drive customers.Agreements signed to expand low-carbon initiativesDuring the event, Dongfeng signed several cooperation agreements related to its Hong Kong market strategy. The company’s subsidiary Dongfeng Import & Export Corporation signed an agreement with Oriental Swan Motor Group Limited, the company’s sole agent in Hong Kong, covering an order for 3,000 vehicles in the Hong Kong market for 2026. The company also announced cooperation agreements with several industry partners covering infrastructure, aviation services, retail operations and equipment services, aimed at supporting the development of smart, low-carbon mobility solutions in Hong Kong.Dongfeng said it will continue to pursue its international expansion strategy under the principle of "In Global For Global," while working with global partners to expand its presence in overseas markets.Company：China Dongfeng Motor Industry Imp. & Exp. Co., Ltd.Email: wangzhenling@dfmc.com.cnWebsite: www.Dongfeng-global.com25/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Thu, Jun 25
HK Grey Market | Keytop Parking Jumps 160%; CFMEE Jumps 66%; WengeAI Jumps 58%; SG Micro Jumps 33%
LINGYI ITECH jumped 10% in Hong Kong’s grey market trading.Lingyi iTech (Guangdong) Co is a China-based company mainly engaged in the manufacturing of artificial intelligence (AI) terminal hardware. As a reliable supplier of AI terminal hardware core components, LY iTECH provides customers worldwide...Tiger News
Thu, Jun 25
HK Stock Extend Declines. HSI Falls 1.6%; Ganfeng Lithium Down 7%; InnoScience Down 6%; MiniMax, Alibaba Down Around 5%; Baidu, Xiaomi, JD Down Around 3%
Hong Kong market fell on Thursday. The Hang Seng Index fell 1.64% to 23,028.81, while the Hang Seng China Enterprises Index fell 2.28% to 7,588.13. The tech-heavy Hang Seng Tech Index fell 1.84% to 4,396.74, showing slightly stronger momentum than the broader market as investors kept a cautiously co...Tiger News
Thu, Jun 25
South Korea's KOSPI Rises 6.25% and Reclaims the 9,000 Level; 2x Leveraged ETF Related to SK Hynix Extends Rally to 24%
South Korea's KOSPI reclaimed the 9,000 level, rising 6.25% on the day. 2x leveraged ETF related to SK Hynix extended rally to 24% while 2x leveraged Samsung ETF jumped 12%.SK Hynix aims to raise tens of billions of dollars in a U.S. listing next month as it battles rivals including Micron Technolog...Tiger News
Thu, Jun 25
Crypto Daily｜Bitcoin Hits Lowest Level Since Oct. 2024; Strategy Shares Dive Under $100 for First Time Since March 2024
Crypto Daily is our column tracking crypto market trends, offering timely insights and valuable updates to keep you informed.Crypto NewsBitcoin Hits Lowest Level Since Oct. 2024 as Bear Market Grinds Into 8th MonthBitcoin (BTC) dropped to $59,023.98 on Wednesday, June 24, its lowest price since Oct....Tiger News
Thu, Jun 25
HK Movers | 2x Leveraged ETF Related to SK Hynix Surges 15% as US Listing Plan Boosts Valuation Hopes
2x leveraged ETF related to SK Hynix surged over 15% in Hong Kong market after the memory chipmaker unveiled its plan for a $29 billion US listing, a move that analysts viewed as boosting valuations through capacity expansion and greater foreign investor access.South Korea's SK Hynix said on Wednesd...Tiger News
Thu, Jun 25
Stocks to watch: OUE Reit, OUE Ltd, Frasers Property, Vicom, UOB
source: TheBusinessTimes[SINGAPORE] The following companies saw new developments that may affect trading of their securities on Thursday (Jun 25):Frasers Property : TQ5 0%: The real estate group on Thursday said it is proposing a S$2.1 billion optimisation of its Frasers Hospitality Trust (FHT) port...Longport
Thu, Jun 25
SG Morning Brief | Micron Blowout Sends Nasdaq Futures Up, Oil Hits $70; Core PCE Today
US OvernightThe S&P 500 dipped 0.10% to 7,358.22 and the Nasdaq slipped 0.43% to 25,476.63, both posting a third straight decline but in a notably calmer session — declines were narrow and indexes closed well off intraday lows. The Dow gained 0.35% (+182.06) to 51,848.90. Oil collapsed further: WTI ...Longport
Thu, Jun 25
Micron Stock Extends Rally to 15%; Chip, Storage Shares Jump with Western Digital, SanDisk up 11%; Seagate Tech up 10%; ARM up 7%
Micron stock extended rally to 15% after strong forecasts. Other chip, storage shares also rallied in after-hours trading. Western Digital, SanDisk up 11%; Seagate Tech up nearly 10%; UMC up 8%; Navitas, ARM up around 7%.Micron forecast quarterly profit and revenue well above expectations on Wednesd...Tiger News
Wed, Jun 24
TCOM: One More Leg Down Before the Reg. Hammer Falls?
Under a cloud of regulatory scrutiny, $Trip.com(TCOM.US) finally released its long-delayed Q1 results on Jun 25. In short: the quarter was decent, with both revenue growth and profit slightly beating estimates. The regulatory probe has not been resolved and there is still no official response.Most n...Dolphin Research
Wed, Jun 24
MU: On a Tear. From Downcycle to Super Growth?
In 2026, the AI hardware spotlight has shifted from compute to storage capacity. As U.S. AI equities wobble, MU’s print is fast becoming the new bellwether.$Micron Tech(MU.US) posted results after hours on Jun 24 (FQ3 FY26, quarter ended May), delivering in style and taking up the AI infra baton. Th...Dolphin Research
Wed, Jun 24
Featured Tools
Top News
Meta Connect 2026 New Product Roundup: Muse Integrated Into AI Glasses, Can It Drive Meta Revenue Growth?
US Stocks Mixed as Dow Drops 160 Points; Tech Stocks Lead, Meta Rises 4.5%
Apple Stock Price Forecast: Where Is the Next Target Price After Record High as iPhone 18 Pro Series Demand Heats Up?
Micron Earnings Preview: Five Key Things Memory Investors Need to Watch
【US Pre-Market】Memory Stocks Including Micron, WDC and SanDisk Fall as Fed Rate-Hike Expectations Rise
